OCEANIA: Real-world Study of Ovarian Cancer Treatment Patterns Across Multiple Lines of Therapy in Argentina and Brazil

Overview

Journal Future Oncol

Specialty Oncology

Date 2024 Jun 11

PMID 38861309

Authors

Claudia Soares

Gabriela Abreu

Thiago Luiz Nogueira da Silva

Juliana Queiroz

Patricia Menezes

Graziela Bernardino

Tatiana Pires

Mariano Carrizo

Rosana Felice

Maria Cecilia Riggi

Florencia Cravero

Andre Luiz Alves Ribeiro de Souza

Laura Jotimliansky

Affiliations

Soon will be listed here.

Abstract

To evaluate real-world data on treatment patterns in Argentina and Brazil in patients with ovarian cancer. This study evaluated de-identified antineoplastic exposure data from a private healthcare provider in Argentina and health claims database (Orizon) in Brazil from 2010 to 2019 and 2015 to 2020, respectively. Platinum-based chemotherapy was the most common first-line therapy (Argentina: n =311 [87.6%]; Brazil: n = 1142 [79.3%]). The proportion of patients receiving platinum-based chemotherapy declined across both populations from first- to second-line, while use of non-platinum-based, targeted, and hormone therapies increased. Duration of platinum-based treatment and time to next treatment decreased from first- to fourth-line. There is an unmet need for effective therapies that can prolong time to next treatment in ovarian cancer in Argentina and Brazil.

References

Wilson M, Pujade-Lauraine E, Aoki D, Mirza M, Lorusso D, Oza A . Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2016; 28(4):727-732. PMC: 6246494. DOI: 10.1093/annonc/mdw663. View

Beachler D, Lamy F, Russo L, Taylor D, Dinh J, Yin R . A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. J Ovarian Res. 2020; 13(1):101. PMC: 7461260. DOI: 10.1186/s13048-020-00691-y. View

Souza Junior P, Szwarcwald C, Damacena G, Stopa S, Vieira M, Almeida W . Health insurance coverage in Brazil: analyzing data from the National Health Survey, 2013 and 2019. Cien Saude Colet. 2021; 26(suppl 1):2529-2541. DOI: 10.1590/1413-81232021266.1.43532020. View

de Oliveira Avellar W, Ferreira E, Vieira A, de Melo A, Aran V . Clinical Cancer Research in South America and Potential Health Economic Impacts. Healthcare (Basel). 2023; 11(12). PMC: 10298265. DOI: 10.3390/healthcare11121753. View

Ferlay J, Colombet M, Soerjomataram I, Parkin D, Pineros M, Znaor A . Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; . DOI: 10.1002/ijc.33588. View

Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M . Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. Int J Environ Res Public Health. 2022; 19(14). PMC: 9317199. DOI: 10.3390/ijerph19148577. View

Ruiz R, Strasser-Weippl K, Touya D, Herrero Vincent C, Hernandez-Blanquisett A, St Louis J . Improving access to high-cost cancer drugs in Latin America: Much to be done. Cancer. 2017; 123(8):1313-1323. DOI: 10.1002/cncr.30549. View

Goss P, Lee B, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J . Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013; 14(5):391-436. DOI: 10.1016/S1470-2045(13)70048-2. View

Cortez A, Tudrej P, Kujawa K, Lisowska K . Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2017; 81(1):17-38. PMC: 5754410. DOI: 10.1007/s00280-017-3501-8. View

10.

Fainstein Day P, Loto M, Glerean M, Russo Picasso M, Lovazzano S, Giunta D . Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab. 2016; 60(6):554-561. PMC: 10522164. DOI: 10.1590/2359-3997000000195. View

11.

Chornokur G, Amankwah E, Schildkraut J, Phelan C . Global ovarian cancer health disparities. Gynecol Oncol. 2012; 129(1):258-64. PMC: 3608795. DOI: 10.1016/j.ygyno.2012.12.016. View

12.

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

13.

Lyon K, Huang J . Bevacizumab Combined with Chemotherapy in Platinum-Resistant Ovarian Cancer: Beyond the AURELIA Trial. Transl Cancer Res. 2021; 9(4):2164-2167. PMC: 8189524. DOI: 10.21037/tcr.2020.02.42. View

14.

Garcia-Subirats I, Vargas I, Mogollon-Perez A, De Paepe P, Silva M, Unger J . Barriers in access to healthcare in countries with different health systems. A cross-sectional study in municipalities of central Colombia and north-eastern Brazil. Soc Sci Med. 2014; 106:204-13. DOI: 10.1016/j.socscimed.2014.01.054. View

15.

Yeon S, Lee M, Ryu H, Song I, Yun H, Jo D . Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer. Medicine (Baltimore). 2023; 102(11):e33271. PMC: 10019173. DOI: 10.1097/MD.0000000000033271. View

16.

Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin R, Tran L . Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clin Lymphoma Myeloma Leuk. 2018; 18(2):152-160. DOI: 10.1016/j.clml.2017.12.012. View

17.

Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P . Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. 2022; 41(4):893-902. DOI: 10.1200/JCO.22.01010. View

18.

Lheureux S, Braunstein M, Oza A . Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019; 69(4):280-304. DOI: 10.3322/caac.21559. View

19.

Paulino E, Nogueira Rodrigues A, Strasser-Weippl K, St Louis J, Bukowski A, Goss P . Barriers to Primary Debulking Surgery for Advanced Ovarian Cancer in Latin America. Int J Gynecol Cancer. 2017; 27(8):1645-1649. DOI: 10.1097/IGC.0000000000001098. View

20.

Johnson E, Nelson C . Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013; 190(1):17-8. PMC: 4114235. DOI: 10.1016/j.juro.2013.04.048. View